Comparative Pharmacology
Head-to-head clinical analysis: DROPERIDOL versus MILPROSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROPERIDOL versus MILPROSA.
DROPERIDOL vs MILPROSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Droperidol is a butyrophenone antipsychotic that acts primarily as a dopamine D2 receptor antagonist. It also exhibits antiemetic effects via blockade of dopamine D2 receptors in the chemoreceptor trigger zone. Additionally, it has alpha-adrenergic blocking properties and can prolong the QT interval by blocking cardiac potassium channels (hERG).
Milprosa is a progesterone receptor agonist that induces and maintains endometrial receptivity, inhibits uterine contractions, and suppresses gonadotropin release.
2.5-10 mg IV/IM every 3-4 hours as needed for nausea and vomiting; for agitation or psychosis in perioperative settings: 0.625-1.25 mg IV/IM, may repeat every 6 hours.
MILPROSA is not a recognized drug; assuming a typo for milrinone? If milrinone: IV loading dose 50 mcg/kg over 10 minutes, then continuous IV infusion 0.375-0.75 mcg/kg/min.
None Documented
None Documented
Clinical Note
moderateDroperidol + Norfloxacin
"Droperidol may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateDroperidol + Ibandronate
"Droperidol may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateDroperidol + Indapamide
"Droperidol may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateDroperidol + Methylphenidate
"The risk or severity of adverse effects can be increased when Droperidol is combined with Methylphenidate."
Terminal elimination half-life: 2.3 hours (range 1.5–4.7 hours). Clinical context: Short half-life allows rapid titration but requires repeated dosing or continuous infusion for sustained effect; accumulation with hepatic impairment.
14 hours (range 10–18); prolonged in renal impairment (up to 40 hours)
Renal (75% as metabolites, <1% unchanged); fecal (22%); biliary excretion contributes to enterohepatic circulation.
Renal (70% unchanged, 20% as inactive metabolites); fecal (10%)
Category A/B
Category C
Antipsychotic
Antipsychotic